TABLE 13Adalimumab efficacy outcomes: uncontrolled follow-up data

TrialType of dataDuration (weeks)OutcomesAdalimumabAdalimumab/placebo
ADEPT51,88,92,93,100104Uncontrolled48ACR 2058.7% (165/281)
ACR 5042.7% (120/281)
ACR 7027.8% (78/281)
HAQ change from baseline: mean (median)(n = 298) −0.3 (0.5)
PASI 5067% (46/69)61% (42/69)
PASI 7558% (40/69)53% (37/69)
PASI 9046% (32/69)44% (30/69)
Mean (SD) TSS change from baseline(n = 115) 0.1 (1.95)(n = 128) 0.8 (4.23)
104ACR 2057.3% (161/281)
ACR 5045.2% (127/281)
ACR 7029.9% (84/281)
HAQ change from baseline: mean (median)(n = 271) −0.3 (0.5)
144Mean (SD) TSS change from baseline(n = 115) 0.5 (4.20)(n = 128) 0.9 (6.36)

From: 3, Assessment of clinical effectiveness

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.